Evidence map›Paper›PMID 41238950›Full record

Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Impact of sarcopenia on paclitaxel-induced peripheral neuropathy in early-stage breast cancer: a prospective observational study (the neuro-sarc study).

İlknur Deliktaş Onur, Pınar Akdur Özdemir, Orhun Akdoğan, Kadriye Başkurt, Melisa Irem Kara, Doga Özdemir Kalkan, Galip Can Uyar, Osman Sütçüoğlu, Berna Öksüzoğlu, Fatih Gürler and 4 more

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06996548 (Investigation of the Relationship Between Sarcopenia and Paclitaxel-Induced Neuropathy in Early Stage Breast Cancer Patients), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06996548 completednot on this map

Investigation of the Relationship Between Sarcopenia and Paclitaxel-Induced Neuropathy in Early Stage Breast Cancer Patients (Neuro-Sarc)

Typeobservational_patient_registrySponsorGazi UniversityRan2024 to 2025Enrolled120ConditionsSarcopenia, Paclitaxel Induced Neuropathy, Breast Carcinoma
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

İlknur Deliktaş OnurDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health Sciences, Ankara, Turkey. ilknurdeliktas382@gmail.com.
Pınar Akdur ÖzdemirDepartment of Radiology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
Orhun AkdoğanDepartment of Medical Oncology, University of Gazi, Ankara, Turkey.
Kadriye BaşkurtDepartment of Medical Oncology, Etlik City Hospital, Ankara, Turkey.
Melisa Irem KaraDepartment of Internal Medicine, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
Doga Özdemir KalkanDepartment of Radiology, Etlik City Hospital, Ankara, Turkey.
Galip Can UyarDepartment of Medical Oncology, Etlik City Hospital, Ankara, Turkey.
Osman SütçüoğluDepartment of Medical Oncology, Etlik City Hospital, Ankara, Turkey.
Berna ÖksüzoğluDepartment of Medical Oncology, Etlik City Hospital, Ankara, Turkey.
Fatih GürlerDepartment of Medical Oncology, University of Gazi, Ankara, Turkey.
Burcu SavranDepartment of Radiology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
Nazan ÇiledağDepartment of Radiology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
Öztürk AteşDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
Fatih YıldızDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health Sciences, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe treatment goal in early-stage breast cancer (ESBC) is disease-free survival, but toxicity should not be ignored as it will affect the quality of life of patients in the later period. Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most significant dose-limiting toxicities in early-stage breast cancer. The incidence of PIPN in patients receiving paclitaxel chemotherapy reaches 64-84%, and > 30% of patients may experience chronic peripheral neuropathy. Although PIPN is a common toxicity, it is unclear which patient group is most frequently affected in ESBC. Furthermore, sarcopenia is known to increase the toxicity of chemotherapeutic agents. In this study, we aimed to evaluate the relationship between sarcopenia and neuropathy.

methodsThis prospective observational study was conducted between November 2024 and May 2025. ESBC patients receiving paclitaxel at a weekly dose of 80 mg/m via a 3-h infusion were included in the study. SMI was calculated by measuring L3 muscle volume from the computed tomography (CT) images taken for staging purposes at the time of diagnosis and adjusting it according to height squared. Sex-specific cutoffs for L3 SMI were used for the diagnosis of sarcopenia. Neuropathy complaints were assessed with the EORTC QLQ-CIPN20 questionnaire before starting paclitaxel treatment and after the completion of treatment. The relationship between sarcopenia and neuropathy as well as other toxicities was evaluated.

resultsSarcopenia was detected in 29 (27.4%) patients. Overall, 50 patients (47.1%) developed paclitaxel-induced peripheral neuropathy (PIPN), including 18 (17.0%) with grade 3, 16 (15.1%) with grade 2, and 16 (15.1%) with grade 1 neuropathy. Five patients (4.7%) were unable to complete 12 weeks of treatment due to grade 3 neuropathy. A significant association was found between age (< 65 vs ≥ 65) (OR 5.2; 95% CI 1.8-15.0; p = 0.002), sarcopenia (OR: 6.5; 95% CI 2.3-18.2; p < 0.001), and neuropathy; no significant association was found between diabetes and concomitant carboplatin use and neuropathy.

conclusionsThis study found a significant association between sarcopenia and geriatric age and PIPN. Toxicity and quality of life are crucial in ESBC patients due to their long-life expectancy. Prospective randomized studies with personalized dosing are needed to minimize the risk of PIPN in this patient group. NCT NUMBER: NCT06996548.

Indexed as

Antineoplastic Agents, PhytogenicBreast NeoplasmsPaclitaxelPeripheral Nervous System DiseasesSarcopeniaAdultAgedFemaleHumansMiddle AgedNeoplasm StagingProspective StudiesQuality of LifeAntineoplastic Agents, PhytogenicPaclitaxelEarly stage breast cancerPaclitaxel-induced peripheral neuropathySarcopenia in breast cancerSarcopenia in ESBCSMI in breast cancer

Identifiers

PMID41238950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.